Merck (MRK) Change in Accured Expenses (2009)
Merck's (MRK) quarterly Change in Accured Expenses came in at -$3.8 billion in Q4 2009, down 4692.41% quarter-over-quarter from -$79.0 million in Q3 2009.
Analysis
Merck (MRK) Change in Accured Expenses (2009) Analysis & Trends
Merck (MRK) has reported Change in Accured Expenses for 1 consecutive years, with -$3.8 billion the latest figure, recorded in Q4 2009.
- On a quarterly basis, Change in Accured Expenses changed N/A year-over-year to -$3.8 billion in Q4 2009; TTM through Dec 2009 was -$5.1 billion, a N/A change from a year earlier, with the FY2025 full-year figure at -$1.8 billion, up 20.92% from the prior year.
- Change in Accured Expenses was -$3.8 billion for Q4 2009 at Merck, down from -$79.0 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at -$79.0 million in Q3 2009 and troughed at -$3.8 billion in Q4 2009.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 2.32 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 1.20 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 360.00 Mn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 55.78 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 212.44 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | -204.33 Mn |